Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden
Standard
Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden. / Dissemond, Joachim; Augustin, Matthias; Dietlein, Michael; Keuthage, Winfried; Läuchli, Severin; Lobmann, Ralf; Münter, Karl-Christian; Stücker, Markus; Traber, Jürg; Vanscheidt, Wolfgang; Strohal, Robert.
in: HAUTARZT, Jahrgang 71, Nr. 10, 10.2020, S. 791-801.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden
AU - Dissemond, Joachim
AU - Augustin, Matthias
AU - Dietlein, Michael
AU - Keuthage, Winfried
AU - Läuchli, Severin
AU - Lobmann, Ralf
AU - Münter, Karl-Christian
AU - Stücker, Markus
AU - Traber, Jürg
AU - Vanscheidt, Wolfgang
AU - Strohal, Robert
PY - 2020/10
Y1 - 2020/10
N2 - Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was a double-blind RCT with 187 patients with VLU. The SPID study was a pilot study with 33 patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88 patients with VLU in different phases of healing. In the REALITY study, a pooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, a significant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.
AB - Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was a double-blind RCT with 187 patients with VLU. The SPID study was a pilot study with 33 patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88 patients with VLU in different phases of healing. In the REALITY study, a pooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, a significant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.
KW - Anti-Ulcer Agents/pharmacology
KW - Humans
KW - Sucrose/analogs & derivatives
KW - Varicose Ulcer/drug therapy
KW - Wound Healing
U2 - 10.1007/s00105-020-04637-9
DO - 10.1007/s00105-020-04637-9
M3 - SCORING: Review
C2 - 32638031
VL - 71
SP - 791
EP - 801
JO - HAUTARZT
JF - HAUTARZT
SN - 0017-8470
IS - 10
ER -